PMC5761185_01
CGMS tracings from individual days, demonstrating (a) maintenance of euglycemia throughout the day. In the setting of pump dysfunction (b), overnight glucagon delivery ceased, precipitating hypoglycemia
40842_2017_53_Fig1_HTML.jpg
PMC5761185_01_40842_2017_53_Fig1_HTML.jpg
Fig1
Review of the data demonstrated maintenance of euglycemia overnight (Fig. 1a). Dependence on glucagon infusion was demonstrated by blood glucose decline during a reported instance of pump technical malfunction (Fig. 1b).
CGMS tracings taken over 1 week after initiation of everolimus. Each color represents an individual day
40842_2017_53_Fig2_HTML.jpg
PMC5761185_01_40842_2017_53_Fig2_HTML.jpg
Fig2
One month after initial presentation, the patient was started on everolimus 5 mg daily, resulting in marked improvement in hypoglycemia (Fig. 2).
CT scan of causative upper right quadrant mass (indicated with dashed line). Scale = 5 cm
40842_2017_53_Fig3_HTML.jpg
PMC5761185_01_40842_2017_53_Fig3_HTML.jpg
Fig3
Abdominal CT scan demonstrated a right upper quadrant mass adjacent to, but not infiltrating the liver, that had increased in size to 14 x 11 cm from 11 x 9 cm on CT two months prior (Fig. 3).